Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Not yet recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Multiple Myeloma 20Leukemia, Myeloid, Acute 8Recurrence 7Neoplasms, Plasma Cell 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma 3Thymoma 2Ovarian Neoplasms 2Carcinoma 2Wilms Tumor 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Small Cell Lung Carcinoma 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Richter's Transformation 1Rhabdoid Tumor 1Prostatic Neoplasms 1Oligodendroglioma 1Neurofibrosarcoma 1Neoplasms 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Melanoma 1MDS 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1

Interventions

pegaspargase 15fludarabine phosphate 15Mycophenolic Acid 14Busulfan 14Tacrolimus 13Cyclophosphamide 13Peripheral Blood Stem Cell Transplantation 12Etoposide 12Dexamethasone 12Whole-Body Irradiation 11Methotrexate 10Gemcitabine 10Antilymphocyte Serum 9Radiotherapy 7Cyclosporine 7spartalizumab 6Oxaliplatin 5Asparaginase 5Transplantation 4Rituximab 4Melphalan 4Flow Cytometry 4tislelizumab 3thymoglobulin 3sintilimab 3selinexor 3pembrolizumab 3Therapeutics 3Polymerase Chain Reaction 3Cord Blood Stem Cell Transplantation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Extranodal NK-T-Cell × selinexor × Clear all
NCT07554482 2026-04-28

Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma

Beijing Tongren Hospital

Phase 2 Not yet recruiting
34 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT07276698 2025-12-11

Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Not yet recruiting
39 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT06573138 2024-08-27

Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL

Ruijin Hospital

Phase 2 Not yet recruiting
18 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡